Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in pretreated patients with advanced NSCLC harbouring HER2 exon 20 mutations
2014-005098-35Phase 2Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Disease control. Started Apr 2015; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-005098-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005098-35.